Detalhe da pesquisa
1.
High prognostic value of measurable residual disease detection by flow cytometry in chronic lymphocytic leukemia patients treated with front-line fludarabine, cyclophosphamide, and rituximab, followed by three years of rituximab maintenance.
Haematologica
; 104(11): 2249-2257, 2019 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-30890600
2.
Cost-utility analysis of venetoclax in combination with obinutuzumab as first-line treatment of chronic lymphocytic leukaemia in Spain.
Farm Hosp
; 46(3): 121-132, 2022 04 27.
Artigo
em Inglês
| MEDLINE | ID: mdl-36183205
3.
[Cytogenetic risk categories in acute myeloid leukemia: a comparison between MRC (Medical Research Council) and SWOG (Southwest Oncology Group) models)]. / Grupos de riesgo citogenético en la leucemia mieloide aguda: comparación de los modelos adoptados por los grupos MRC (Medical Research Council, del Reino Unido) y SWOG (Southwest Oncology Group, de EE.UU.).
Med Clin (Barc)
; 121(4): 121-5, 2003 Jun 28.
Artigo
em Espanhol
| MEDLINE | ID: mdl-12867014